[en] OBJECTIVE: The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice. METHODS: EXPERT was an international, multicenter, prospective, uncontrolled, non-interventional cohort study of patients treated with riociguat. Patients were followed for at least 1 year and up to 4 years from enrollment or until 30 days after stopping riociguat treatment. Primary safety outcomes were adverse events (AEs) and serious adverse events (SAEs) coded using Medical Dictionary for Regulatory Activities preferred terms and System Organ Classes version 21.0, collected during routine clinic visits (usually every 3-6 months) and collated via case report forms. RESULTS: In total, 326 patients with PAH were included in the analysis. The most common AEs in these patients were dizziness (11.7%), right ventricular (RV)/cardiac failure (10.7%), edema/peripheral edema (10.7%), diarrhea (8.6%), dyspnea (8.0%), and cough (7.7%). The most common SAEs were RV/cardiac failure (10.1%), pneumonia (6.1%), dyspnea (4.0%), and syncope (3.4%). The exposure-adjusted rate of hemoptysis/pulmonary hemorrhage was 2.5 events per 100 patient-years. CONCLUSION: Final data from EXPERT show that in patients with PAH, the safety of riociguat in clinical practice was consistent with clinical trials, with no new safety concerns identified and a lower exposure-adjusted rate of hemoptysis/pulmonary hemorrhage than in the long-term extension of the Phase 3 trial in PAH.
Vonk Noordegraaf, A., et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur. Respir. J., 53(1), 2019, 10.1183/13993003.01900-2018.
Humbert, M., et al. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur. Respir. J., 53(1), 2019, 10.1183/13993003.01887-2018.
Simonneau, G., et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J., 53(1), 2019, 10.1183/13993003.01913-2018.
Galiè, N., et al. ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT). Eur. Respir. J. 46:4 (2015), 903–975.
Humbert, M., Ghofrani, H.A., The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax 71:1 (2016), 73–83.
Bayer AG, Adempas (riociguat tablets): EU summary of product characteristics. Available from https://www.ema.europa.eu/en/documents/pr oduct-information/adempas-epar-product-information_en.pdf. (Accessed 18 November 2020)
Bayer AG, Adempas US prescribing information. 2018 Available from https://labeling.ba yerhealthcare.com/html/products/pi/Adempas_PI.pdf. (Accessed 18 November 2020)
Ghofrani, H.A., et al. Riociguat for the treatment of pulmonary arterial hypertension. N. Engl. J. Med. 369:4 (2013), 330–340.
Ghofrani, H.A., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N. Engl. J. Med. 369:4 (2013), 319–329.
Ghofrani, H.A., et al. Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 4 (2016), 361–371.
Rubin, L.J., et al. Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). Eur. Respir. J. 45:5 (2015), 1303–1313.
Simonneau, G., et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir. Med. 4:5 (2016), 372–380.
Simonneau, G., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur. Respir. J. 45:5 (2015), 1293–1302.
Simonneau, G., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 62:Suppl 25 (2013), D34–D41.
Simonneau, G., et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54:1 Suppl (2009), S43–S54.
Gaine, S., Simonneau, G., The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension. Eur. Respir. Rev. 22:130 (2013), 487–494.
Sitbon, O., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J. Am. Coll. Cardiol. 40:4 (2002), 780–788.
Humbert, M., et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36:3 (2010), 549–555.
Farber, H.W., et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest 148:4 (2015), 1043–1054.
Miller, D.P., et al. Survivor bias and risk assessment. Eur. Respir. J. 40:3 (2012), 5350–5532.
Badesch, D.B., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 137:2 (2010), 376–387.
Humbert, M., et al. Pulmonary arterial hypertension in France: results from a national registry. Am. J. Respir. Crit. Care Med. 173:9 (2006), 1023–1030.
Hoeper, M.M., et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur. Respir. J. 50:2 (2017), 1–10.
Benza, R.L., et al. Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (REVEAL). Circulation 122:2 (2010), 164–172.
Gall, H., et al. The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J. Heart Lung Transplant., 2017, S1053–S2498.
Vachiery, J.L., et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: the VOLibris Tracking Study. J. Heart Lung Transplant. 36:4 (2017), 399–406.
Trammell, A.W., et al. EXPRESS: mortality in U.S. veterans with pulmonary hypertension: a retrospective analysis of survival by subtype and baseline factors. Pulm. Circ., 2019 2045894019825763.
McGoon, M.D., et al. Pulmonary arterial hypertension: epidemiology and registries. J. Am. Coll. Cardiol. 62:25 Suppl (2013), D51–D59.
Ghofrani, Hossein-Ardeschir, et al. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respir. Med., 2020 In this issue.
